S Korea blazes trail to grant second approval worldwide to Pfizer's Xalkori
This article was originally published in Scrip
Executive Summary
Pfizer's novel oncology product Xalkori (crizotinib) has been approved and launched in South Korea, its second market worldwide, for the treatment of locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).